iBio, Inc. (NYSE: IBIO) announced Thursday that immunization studies for its SARS-CoV-2 Virus-Like Particle (“VLP”) program (“IBIO-200”) are proceeding at Texas A&M University System (“TAMUS”) laboratories. According to the Company the work is being performed as part of the Master Joint Development Agreement established between iBio and TAMUS in 2016.
“This next stage of work on IBIO-200 is critically important as we seek to quickly enter the clinic with one of our VLP candidates,” said Tom Isett, Co-Chairman & Chief Executive Officer of iBio. “As we optimize our choice of adjuvants with both VLP types we have developed, we are fortunate to have a strong relationship with TAMUS that allows us to rapidly bring their deep insight into the pathogenesis of coronaviruses and experience with vaccine development to the task.”
iBio created its proprietary VLP candidates in just a few weeks using the FastPharming System™. The Company then claims that researchers deployed this plant-based expression platform’s production capabilities to deliver VLPs suitable for further development just weeks after the biologics were designed.
“We see strong potential for the IBIO-200 program given that we have both the glycosylated and non-glycosylated iBio VLPs as options for development,” said Dr. James Samuel, Head of the Department of Microbial Pathogenesis and Immunology at Texas A&M University. “We look forward to completing the preclinical immunization studies for iBio to determine the optimal combination of VLP and adjuvant to advance to human clinical trials.”
Enrico CapjaApr 01, 2020 at 08 31 am
Originally built in 2010 with funding from the U.S. Defense Advanced Research Projects Agency (DARPA), iBio’s FastPharming Facility was part of the “Blue Angel” initiative to establish facilities capable of rapid delivery of medical countermeasures in response to a disease pandemic.
See also https://www.youtube.com/watch?v=38vEkF6VaFs